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Background: Bile salt-stimulated lipase (BSSL) is one of three main lipases
responsible for digestion of dietary triglycerides. BSSL is secreted by the mammary
gland as a constituent of mother’s milk and by the pancreas. The safety results from
the ﬁrst clinical study with rhBSSL produced in CHO (chinese hamster ovary) cells
in adults with CF are presented here.
Patients & Methods: Fifteen patients diagnosed with CF and PI entered a baseline
period (BP) using no pancreatic enzyme treatment (PET), followed by a treatment
period (TP). Both periods lasted 6−7 days and during the last 72-hours a fat balance
was obtained for determining the coefﬁcient of fat absorption (CFA). Fourteen
patients entered the TP and were treated with 170mg oral rhBSSL t.i.d. During
BP and TP, patients were on a diet containing 100 g fat/day and hospitalized. CFA,
safety and tolerability of rhBSSL were assessed.
Results: Fourteen patients, 20 years old [18−54] (median age [range]), constituted
the safety population. Five (35%) and 11 (79%) patients experienced an adverse
event (AE) during the BP and TP, respectively. The most common AE was mild
abdominal pain which all resolved within 3 days. Two serious AEs occurred
(pulmonary exacerbations unlikely to be related to active treatment). Due to protocol
deviations relating to stool collection only 9 patients were included in the analysis
of CFA. The CFA increased with 6.9% (95%CI: −5.0, 18.9; P = 0.22) during TP
compared to BP.
Conclusions: In this study, treatment with rhBSSL in adult CF patients was safe
and well tolerated. Further studies are needed to establish its future role in CF
patients.
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Nebulizers are the only nasal devices available on the market to treat sinusitis with
antibiotics. Based on previous studies, speciﬁc nasal jet nebulizers using sound
effects are currently the best option for targeting antibiotic aerosols to the site of
infection in case of chronic rhinosinusitis. To our knowledge, there are no studies
describing with precision the aerosol deposition obtained with this nasal nebulizer
equipped with a 100Hz-sound system (nasal sonic nebulizer). The aim of the present
work was to quantify the amount of aerosol deposited in the different parts of the
airways with NL11S nasal sonic jet nebulizer (DTF Medical, Saint Etienne, France).
Seven healthy, non-smoking, male volunteers aged from 21 to 36 years, with a mean
weight of 77±10 kg, were included in a single-center study. NL11S sonic nebulizer
was loaded with 99mTc-DTPA and scintigraphies were performed after 10min of
nebulization with a gamma camera. Aerosol deposition in the nasal cavity, the
maxillary sinuses, the ethmoid, the stomach and the lungs were imaged. Regions of
interest of the nasal cavity and lungs were previously deﬁned from 81mKr ventilation
images.
Aerosol deposition (% of aerosol deposited) was 73±10% in the upper airways and
27%±10% in the lungs. The sonic aerosol was deposited below the nasal valve
including maxillary sinuses (5±2%) and ethmoidal (11±2 %) regions. Total nasal
deposition was 9.6±1.9% of the nebulizer charge.
The nasal sonic jet nebulizer NL11S can be used efﬁciently with drugs to target
the nasal cavity including the ethmoid and the sinuses.
Funded by DTF Medical.
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In the present study we aimed to evaluate adherence to inhaled rhDNase using data
downloaded from a special inhalation device.
In a clinical trial, patients aged 6 to 18 years inhaled 2.5ml rhDNase once daily
for 4 weeks using the AKITA2® APIXNEB device. The AKITA2 device was used
in two different settings to deliver the aerosol preferably in the (1) central or in the
(2) small airways, and patients were equally randomised to these treatment groups.
The device logged date, time, dose and duration of each inhalation. These data were
downloaded to calculate adherence rates. In addition, patients used diary cards to
provide written information on their use of medication.
49 subjects participated in the trial and 43 provided data on adherence. Using
data from the devices, mean adherence rate was 88% (SD 17%) for daily doses.
39 patients had a total dose compliance above 70%. Results from diary cards
signiﬁcantly overestimated adherence rates (pChi−Quadrat<0.001). 88% of protocol
entries matched to data logging of the AKITA2 inhalation device. No difference in
adherence was observed during working days and weekend. Treatment adherence
was not inﬂuenced by the treatment group (mean DDC central 87% (SD 16%) vs.
88% (SD 19%) in small airway deposition). Patients aged 6 to 12 had no difference
in adherence compared with adolescents [mean DDC 90% (SD 19%) vs. 86%
(SD 16%)], and patients with worse lung function didn’t have higher adherence
rates than those with milder lung disease [mean DDC 87% (SD 19%) vs. 89%
(SD 15%)].
The use of adherence data from inhalation devices facilitates communication be-
tween patients and health professionals aiming at removing obstacles to adherence.
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Introduction: More efﬁcient treatment of obstructed small airways is needed in
CF. This study investigated whether efﬁcient deposition of dornase alfa in the small
airways using a new smart nebulizer improves small airway obstruction.
Methods: In a multi-center, double-blind, randomized controlled clinical trial CF
patients on maintenance treatment with dornase alfa were switched to a smart
nebulizer (Akita2® APIXNEB) and treated with 2.5ml dornase alfa once daily for
4 weeks. Patients were randomized to small airways deposition or large airways
deposition, the latter simulating the aerosol deposition pattern of conventional neb-
ulizers. Primary outcome parameter was Forced Expiratory Flow at 75% of Forced
Vital Capacity (FEF75). Analysis of covariance was used to assess differences in
treatment effect between the two groups.
Results: FEF75 increased by 0.7 SDS (5.2% predicted) in the large airways group
and 1.2 SDS (8.8% predicted) in the small airways group. Intention to treat analysis
did not show a signiﬁcant difference in treatment effect between groups. Per
protocol analysis showed a signiﬁcant difference between the groups (p = 0.04)
in absolute FEF75 (L/s) and a trend (p = 0.06) for FEF75 z-score favoring small
airways deposition.
Conclusions: Improved delivery of dornase alfa using a smart nebulizer that
coaches patients in correct inhalation technique resulted in substantial improvement
of FEF75 in children with stable CF on dornase alfa maintenance treatment. In
adherent children a trend was observed in favor of small airways deposition.
Optimizing inhalation technique and adherence are crucial to obtaining maximal
response to inhaled medications.
